This research uses a high-throughput screening platform called EpiScan to identify HIV peptides that bind strongly to MHC molecules and appear on infected cell surfaces. By discovering these immune-visible targets, the work aims to improve detection and elimination of hidden HIV reservoirs, supporting the development of future HIV therapies.

This research investigates how misfolded Islet Amyloid Polypeptide (IAPP), a protein associated with Type 2 diabetes, affects blood clot formation. Laboratory experiments showed that misfolded IAPP creates unusually dense and resilient clots. These findings may help explain elevated cardiovascular risk in diabetes and identify new targets for preventing heart attacks and strokes.

This research develops soft, tissue-like implantable sensors capable of monitoring molecular signals inside the body in real time. By combining high-performance electronics with flexible, biocompatible materials, these devices could detect inflammation, stress, or organ damage before symptoms arise, enabling earlier diagnosis and more personalized healthcare.

This research investigates macrophages, immune cells that regulate infection, tissue repair, and cancer responses. Through laboratory experiments and machine-learning models, it aims to predict macrophage function across different diseases and patients. The work could improve prognosis, guide treatments, evaluate drug safety, and forecast recovery following major illnesses and injuries.

This research investigates how cells select which protein fragments, or peptides, to display to the immune system. Contrary to previous assumptions, peptide presentation appears highly curated rather than random. Understanding these selection rules could improve cancer immunotherapy, enhance antiviral treatments, and provide new insights into autoimmune diseases.

This research investigates how glioblastoma brain cancer cells invade healthy brain tissue. Using patient-derived tumor organoids and traction force microscopy, the study measures how cancer cells generate and apply forces to move through the brain. Understanding these invasion mechanisms could help develop therapies that slow tumor spread and improve patient survival.

This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

This research develops an inhalable treatment for lung infections using nanocrystalline silver with both antimicrobial and anti-inflammatory properties. By adapting proven skin-based technology for respiratory delivery via nebulization, it targets both pathogens and harmful inflammation, addressing a major gap in lung disease treatment affecting over a billion people worldwide.

This research targets rare genetic diseases caused by frameshift mutations using antisense oligonucleotides as “genetic band-aids.” By masking faulty DNA segments, it restores functional protein production. Demonstrated in muscular dystrophy models, this approach offers a scalable strategy to treat multiple rare diseases, addressing a major gap where most conditions lack effective therapies.